Johnson & Johnson $JNJ Stock Position Cut by Busey Bank

Key Points

• Busey Bank reduced its Johnson & Johnson stake by 10.4% in the third quarter, selling 28,745 shares and retaining 248,469 shares valued at approximately $65.8 million.
• Other major institutions increased their positions, and institutional investors collectively own 69.55% of J&J. However, company insiders sold $17.3 million worth of shares over the past three months.
• J&J recently exceeded quarterly earnings and revenue estimates and announced a $1.34 quarterly dividend, but investors face concerns over premium valuation, slowing MedTech growth and potential future earnings pressure.

Busey Bank lowered its stake in shares of Johnson & Johnson (NYSE:JNJ - Free Report) by 10.4% during the third quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 248,469 shares of the company's stock after selling 28,745 shares during the period. Johnson & Johnson accounts for 1.6% of Busey Bank's holdings, making the stock its 18th biggest position. Busey Bank's holdings in Johnson & Johnson were worth $65,779,000 as of its most recent filing with the Securities & Exchange Commission.

Several other institutional investors and hedge funds have also recently bought and sold shares of the business. Jupiter Topco LLC acquired a new position in Johnson & Johnson in the 2nd quarter worth about $1,967,399,000. Corient Private Wealth LP lifted its stake in Johnson & Johnson by 127.3% during the 2nd quarter. Corient Private Wealth LP now owns 6,060,922 shares of the company's stock valued at $1,539,292,000 after acquiring an additional 3,393,981 shares in the last quarter. Wellington Management Group LLP increased its position in shares of Johnson & Johnson by 12.5% during the second quarter. Wellington Management Group LLP now owns 22,588,696 shares of the company's stock valued at $5,736,851,000 after acquiring an additional 2,513,321 shares during the last quarter. Amundi raised its stake in shares of Johnson & Johnson by 17.5% during the 1st quarter. Amundi now owns 13,406,820 shares of the company's stock worth $3,277,163,000 after purchasing an additional 2,001,139 shares during the period. Finally, SEB Asset Management AB bought a new position in shares of Johnson & Johnson during the 1st quarter valued at approximately $314,468,000. Institutional investors own 69.55% of the company's stock.

Insider Buying and Selling

In other news, EVP Timothy Schmid sold 33,597 shares of the firm's stock in a transaction on Wednesday, September 2nd. The shares were sold at an average price of $274.74, for a total value of $9,230,439.78. Following the sale, the executive vice president directly owned 25,447 shares in the company, valued at approximately $6,991,308.78. This trade represents a 56.90% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, EVP Elizabeth Forminard sold 15,918 shares of the stock in a transaction that occurred on Thursday, August 6th. The shares were sold at an average price of $257.00, for a total transaction of $4,090,926.00. Following the completion of the transaction, the executive vice president owned 16,994 shares in the company, valued at $4,367,458. This represents a 48.37% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders sold 64,515 shares of company stock valued at $17,271,766 in the last three months. 0.16% of the stock is owned by corporate insiders.

Johnson & Johnson News Summary

Here are the key news stories impacting Johnson & Johnson this week:

• Positive Sentiment: Icotyde, J&J’s oral plaque-psoriasis treatment, is reportedly gaining traction among U.S. dermatologists and being prescribed earlier in the treatment process. Strong adoption could support pharmaceutical growth and help offset declines in older products. Does Johnson & Johnson Have a New Edge in Plaque Psoriasis?
• Positive Sentiment: J&J presented 26 abstracts at TCT 2026 supporting the safety, efficacy and cost-effectiveness of its Impella heart pumps. The data may strengthen the long-term outlook for the MedTech portfolio despite recent weakness. Johnson & Johnson Presents Impella Data at TCT 2026
• Positive Sentiment: J&J continues to be highlighted as a dependable dividend stock, supported by more than five decades of annual payout increases. That income profile can provide downside support for long-term investors. Dividend Kings With 50-Plus Years of Payout Increases
• Neutral Sentiment: J&J’s recent performance has been strong, with shares reportedly up 42% over the past year, helped by progress toward resolving talc litigation and growth from newer medicines. Analysts are debating whether that advance has already priced in much of the improvement. Johnson & Johnson Is Up 42% in a Year
• Neutral Sentiment: Broker sentiment remains generally favorable, but the article questions how much weight investors should place on consensus recommendations as J&J trades near its 52-week high and at an elevated earnings multiple. Johnson & Johnson Broker Ratings
• Negative Sentiment: MedTech growth slowed in the third quarter because of international-market challenges and weakness at Abiomed. Investors may be concerned that a rebound in the fourth quarter will not fully offset the segment’s short-term disappointment. JNJ MedTech Segment Disappoints in Q3
• Negative Sentiment: Analysts see potential earnings pressure in 2027, while the market is already assigning a premium valuation after strong gains. That combination increases the risk of profit-taking if growth slows. Johnson & Johnson Strong Q3 Growth, but 2027 Could Test Earnings
• Negative Sentiment: Pomerantz announced an investigation into potential claims on behalf of J&J investors. Although such announcements do not establish wrongdoing, they add headline and litigation risk. Pomerantz Investor Investigation

Johnson & Johnson Price Performance

Shares of JNJ opened at $273.39 on Friday. The company has a quick ratio of 0.74, a current ratio of 1.02 and a debt-to-equity ratio of 0.44. Johnson & Johnson has a twelve month low of $185.12 and a twelve month high of $282.02. The company has a market cap of $658.13 billion, a price-to-earnings ratio of 25.84, a price-to-earnings-growth ratio of 2.72 and a beta of 0.21. The company has a 50 day moving average of $265.74 and a two-hundred day moving average of $246.94.

Johnson & Johnson (NYSE:JNJ - Get Free Report) last announced its quarterly earnings results on Tuesday, October 13th. The company reported $2.59 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $2.53 by $0.06. The firm had revenue of $25.40 billion for the quarter, compared to the consensus estimate of $25.38 billion. Johnson & Johnson had a net margin of 16.20% and a return on equity of 31.64%. The firm's quarterly revenue was up 5.9% compared to the same quarter last year. During the same period in the prior year, the firm posted $2.80 earnings per share. Johnson & Johnson has set its FY 2026 guidance at 11.050-11.150 EPS. As a group, analysts predict that Johnson & Johnson will post 11.12 earnings per share for the current fiscal year.

Johnson & Johnson Dividend Announcement

The business also recently announced a quarterly dividend, which will be paid on Tuesday, December 8th. Investors of record on Tuesday, November 24th will be issued a $1.34 dividend. The ex-dividend date is Tuesday, November 24th. This represents a $5.36 dividend on an annualized basis and a yield of 2.0%. Johnson & Johnson's dividend payout ratio (DPR) is 81.21%.

Analyst Upgrades and Downgrades

Several research analysts have commented on JNJ shares. Weiss Ratings downgraded Johnson & Johnson from a "buy (b+)" rating to a "buy (b-)" rating in a research note on Friday, October 23rd. Erste Group Bank cut shares of Johnson & Johnson from a "buy" rating to a "hold" rating in a research report on Wednesday, October 21st. Argus set a $300.00 price target on Johnson & Johnson in a research note on Wednesday, July 29th. Royal Bank Of Canada dropped their price objective on Johnson & Johnson from $290.00 to $280.00 and set an "outperform" rating on the stock in a research report on Wednesday, October 14th. Finally, UBS Group set a $270.00 price objective on Johnson & Johnson in a research note on Wednesday, October 14th. One research analyst has rated the stock with a Strong Buy rating, seventeen have issued a Buy rating and eight have assigned a Hold rating to the company's stock. According to MarketBeat, Johnson & Johnson currently has an average rating of "Moderate Buy" and a consensus target price of $275.92.

Johnson & Johnson Profile

Johnson & Johnson NYSE: JNJ is a global healthcare company headquartered in New Brunswick, New Jersey. Founded in 1886, the company develops and markets products and services for patients, healthcare professionals and institutions worldwide.

Johnson & Johnson operates through two principal segments: Innovative Medicine and MedTech. Innovative Medicine focuses on pharmaceuticals for areas such as immunology, oncology, neuroscience, infectious diseases and cardiovascular conditions.

Want to see what other hedge funds are holding JNJ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Johnson & Johnson (NYSE:JNJ - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.